Rewind Therapeutics

Remyelination
#Financing #Multiple sclerosis #Neurology #Neuroscience #Rewind Therapeutics

New financing supports Rewind’s GPR17 remyelination programme

Rewind Therapeutics has announced additional financing to advance the development of its lead GPR17 antagonist programme, a potential disease modifying oral therapy intended to promote remyelination and restore neurological function in multiple sclerosis (MS).  MS is characterised by damage to myelin, but there are no approved therapies… Read More

#News